Background and Purpose-In patients with severe bacterial meningitis, norepinephrine is often infused to increase mean arterial pressure (MAP). This increases cerebral blood flow (CBF), but it is unknown if this increase is caused by impaired cerebral autoregulation or by a cerebral effect of norepinephrine through increased cerebral metabolism. The latter possibility implies a CBF-metabolism coupling. This has not been studied during meningitis. We studied the effect of norepinephrine and propofol on CBF and oxidative metabolism in patients with severe bacterial meningitis. Methods-In seven patients with pneumococcal meningitis and 7 healthy subjects, norepinephrine was infused intravenously; patients also underwent intravenous propofol infusion. Global CBF was measured by the Kety-Schmidt technique; cerebral oxidative metabolism and net flux of norepinephrine and epinephrine were calculated from measured arterial-to-jugular venous concentration differences (a-vD). [54 to 77] mL/100 g per minute) but remained unchanged in controls. The cerebral metabolic rate of oxygen (CMRO 2 ) decreased in patients and remained unchanged in controls. No cerebral net flux of norepinephrine or epinephrine was found at any time in the 2 groups. During propofol infusion, CMRO 2 , and the a-vDO 2 decreased whereas CBF was unchanged. Conclusions-In patients with severe bacterial meningitis, norepinephrine increases both MAP and CBF but not CMRO 2 , indicating impaired autoregulation. Propofol reduces CBF relatively less than cerebral metabolism, suggesting a resetting of the CBF-CMRO 2 relationship.
C ritically ill patients with severe acute bacterial meningitis are often treated with norepinephrine to increase mean arterial pressure (MAP) and thereby maintain adequate organ perfusion. It has previously been shown that patients with acute bacterial meningitis have impaired cerebral blood flow (CBF) autoregulation, because a median increase in MAP of 46% by norepinephrine infusion is associated with a median increase in CBF of 36%, as assessed by transcranial Doppler ultrasonographic measurement of the flow velocity in the middle cerebral artery. 1 However, an alternative explanation could be that norepinephrine leaks over a disrupted blood-brain barrier, known to occur in meningitis, 2,3 thereby increasing cerebral metabolism and, subsequently, CBF. 4, 5 Further, sedation is often instituted in patients with bacterial meningitis and impaired consciousness, the objective being to reduce cerebral metabolism and CBF, which in turn is expected to reduce intracranial pressure (ICP) and vasogenic edema. Propofol, a short-acting sedative, is the drug of choice in many intensive care units. However, the effect of propofol on cerebral oxidative metabolism and CBF has not been established in meningitis patients, and it is unknown whether the metabolic coupling is preserved. 6 The present study addresses the effect of norepinephrine and propofol on global CBF, oxidative metabolism, and net flux of catecholamines in patients with severe bacterial meningitis as compared with healthy volunteers. We hypothesized the following: (1) during a norepinephrine infusion effectively increasing MAP, CBF increases in patients but remains unchanged in volunteers, whereas cerebral oxidative metabolism and net fluxes of catecholamines are unchanged in both groups; and (2) during propofol infusion, cerebral oxidative metabolism and CBF will decrease in parallel in patients with meningitis. 
Materials and Methods

Patients
Study Design
The patients were studied as soon after inclusion as possible; volunteers reported to the department after an overnight fast. The subject rested in the supine position with slightly elevated head. Catheters for blood sampling were placed in the right internal jugular vein with the tip in the jugular bulb and in a radial artery. A peripheral venous catheter was used for tracer infusion.
Patient Study
Global CBF, cerebral metabolic rates (CMR) of glucose (glu), and lactate (lac) and cerebral net fluxes (J) of norepinephrine and epinephrine were measured sequentially during 3 conditions: baseline, norepinephrine infusion, and propofol infusion.
Norepinephrine Infusion
Norepinephrine was infused intravenously at rates sufficient to increase MAP by at least 20 mm Hg from baseline. The infusion rate was titrated so that the target MAP was reached 18 minutes after the start of tracer infusion (10 minutes before start of blood sampling) and maintained unchanged until the end of blood sampling.
Propofol Infusion
Propofol was infused intravenously at rates routinely used for deep sedation. The infusion rate was superimposed on the baseline settings of sedatives and analgesics. The target infusion rate of propofol was set at the start of tracer infusion (28 minutes before blood sampling) and maintained until the end of blood sampling. Norepinephrine was infused whenever needed to maintain MAP unchanged from baseline.
The order of measurements was not randomized. Measurements were spaced 1 hour apart (30-minute washout phase plus 30-minute tracer infusion), ie, total study duration was Ϸ3 hours. The position of the patient, ventilator settings, and infusion rates of sedatives and sympathomimetics, except for the changes stated previously, were maintained unchanged throughout the study (Table 2) . A physician was present in the room at all times during the study, continuously monitoring the patient for hemodynamic and neurological changes; no complications occurred.
Volunteer Study
CBF, CMR, and J were measured at baseline and during an infusion of norepinephrine at rates as stated for patients. No propofol was infused. The order of the baseline and norepinephrine studies was randomized with a 1-hour interval between measurements. No complications occurred.
Measurements
Global CBF, CMR, and J were measured using the Kety-Schmidt technique 8 in the desaturation mode 9 using 133 Xe as previously described. 10, 11 Paired blood samples were drawn at prespecified times and counted on a scintillation counter (Cobra II; Packard Instruments) yielding background-corrected and decay-corrected activity of 133 Xe in cpm/g blood. Paired full-blood samples were analyzed on a blood gas analyzer (ABL 715; Radiometer) for arterial (a) and jugular venous (v) oxygen tension (pO 2 ), oxygen saturation (SO 2 ), and carbon dioxide tension (pCO 2 ).
Glucose and lactate concentrations were measured on fluoridetreated plasma, which was stored at Ϫ20°C until analyzed by an enzymatic method (YSI 2700; Yellow Spring Instruments). Plasma glucose concentrations were converted to whole-blood concentrations.
Glutathione-treated and EGTA-treated plasma were stored at Ϫ80°C until measurement of norepinephrine and epinephrine concentration by high-performance liquid chromatography (HewlettPackard) with electrochemical detection. 12 For calculation of J, plasma concentrations were converted to whole-blood concentrations.
Calculations
Calculations were performed as previously described. 10, 11 Briefly, global CBF was calculated from the height-over-area equation, 13 using a hemoglobin (Hb)-corrected as given by Høedt-Rasmussen et al. 14 Arterial and jugular venous concentrations and the arterialto-jugular venous concentration difference (a-vD) of O 2 were calculated from measured values of Hb, P a O 2 , and S a O 2 . CMRO 2 , CMR glu , and CMR lac and the cerebral net flux, J, of catecholamines were calculated by the Fick principle 15 of multiplying CBF by the a-vD of the substance. By definition, positive values of CMR or J indicate consumption or net influx, and negative values indicate production or net efflux.
The index of autoregulation and the index of metabolic coupling were calculated as follows. First, the estimated cerebrovascular resistance, CVR e , was calculated as
This equation substitutes MAP for cerebral perfusion pressure, ie, it assumes that the ICP is zero. This assumption was made because ICP monitoring was not available. In patients with increased ICP, MAP will be higher than the cerebral perfusion pressure, ie, the absolute value of CVR will be overestimated. This will be of less importance during repeated measurements, provided that the ICP is unchanged between measurements. The autoregulation index (ARI) was calculated from the values obtained at baseline and during norepinephrine infusion as relative change in CVR e divided by relative change in MAP, 16 Values are medians (ranges). *Significantly lower than control at baseline. †Significantly higher than same group at baseline. ‡Significantly lower than same group at baseline. 
Results
Systemic Parameters
Cerebral Blood Flow and Metabolism
At baseline, patients had lower CBF (PϽ0.01), a-vDO 2 (PϽ0.001), CMRO 2 (PϽ0.001), and CMR glu (PϽ0.05) than controls (Table 3) . CMR lac did not differ between patients and controls.
In patients, CBF increased during norepinephrine infusion (PϽ0.05), whereas CMRO 2 decreased slightly (PϽ0.05; Table 3 ; Figure 1) ; CMR glu and CMR lac were unchanged. In controls, CBF and CMR remained unchanged. 
During propofol infusion in meningitis patients (
Norepinephrine and Epinephrine
At baseline, the arterial plasma concentration of norepinephrine did not differ between groups, whereas patients had higher concentrations of epinephrine than controls (PϽ0.05; Table 4 ). Norepinephrine concentrations increased in both groups during norepinephrine infusion and in meningitis patients during propofol infusion (for all, PϽ0.05). The cerebral net flux of catecholamine did not differ from zero in either of the groups at baseline, during norepinephrine infusion, or during propofol infusion.
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Discussion
The finding that CBF increased along with MAP agrees with previous studies that have reported an impaired CBF autoregulation in meningitis patients using external detection of 133 Xe washout 17 and transcranial Doppler ultrasound. 1, 18 It also supports similar findings in an experimental model of meningitis. 19 In the previous human studies, cortical CBF may have been overrepresented as compared with white matter flow. Using the Kety-Schmidt technique, we found that global CBF, not just cortical CBF, increases during norepinephrine infusion in humans with bacterial meningitis. We believe that neither the sedatives-analgesics administered nor the presence of hypocapnia relative to controls explain the disturbed CBF autoregulation in the patients. Thus, preserved autoregulation has been demonstrated in humans during sedation with midazolam and fentanyl 20 and with propofol. 21 Moreover, hypocapnia partially restores autoregulation in meningitis patients. 18 In contrast, the high temperature in most patients may be of some significance, because hypothermia restores autoregulation in patients with fulminant hepatic failure. 22 The use of norepinephrine in meningitis patients has been viewed as problematic, because it may traverse the disrupted blood-brain barrier, increase global cerebral metabolism and CBF, and aggravate vasogenic edema. We found that at clinically relevant doses of norepinephrine, global CBF increased without a concomitant increase in cerebral oxidative metabolism. Moreover, no net cerebral uptake of norepinephrine was observed over a wide range of arterial plasma concentrations. This indicates that the increase in CBF was not mediated by an increase in brain metabolism, but rather was a consequence of impaired CBF autoregulation present in the early stages of acute bacterial meningitis.
Norepinephrine increases glycolysis and oxidative metabolism in astrocytes. 23 Its penetration over the intact bloodbrain barrier is poor 24 but increases in animal models after barrier disruption by intracarotid injection of hypertonic urea; simultaneously, CBF and metabolism increase. 4, 5 In bacterial meningitis, a certain extent of barrier disruption is likely to occur. 2, 3 However, 2 separate lines of evidence from the present study suggest that at clinically relevant dosing rates, intravenously infused norepinephrine does not enter the brain to an extent that increases global cerebral metabolism. First, no net flux was observed in patients or healthy subjects at baseline, during norepinephrine infusion, or in patients during propofol infusion. Secondly, even during high infusion rates of norepinephrine no effects were observed to suggest an independent cerebral action of norepinephrine. The slight reduction in CMRO 2 observed during norepinephrine infusion may be caused by an underestimation of the CBF change inherent in the Kety-Schmidt technique. 9 Sedatives such as propofol are often used in meningitis patients; a reduction in cerebral metabolism is suggested to be beneficial as it is assumed to be accompanied by a parallel reduction in CBF, cerebral blood volume, and ICP. This assumption has not previously been tested in humans with bacterial meningitis. In this study, propofol reduced CMRO 2 but failed to reduce CBF. The change in the a-vDO 2 also indicates a resetting of the relationship between CMRO 2 and CBF. Several studies have found an unchanged a-vDO 2 in healthy subjects during propofol sedation, 25, 26 even at doses leading to an isoelectric electroencephalogram. 27 Taken together, the results suggest that cerebral metabolic coupling is impaired in patients with bacterial meningitis.
The low a-vDO 2 and CMRO 2 in meningitis patients at baseline agree with previous findings in these patients. 10, 17 Patients were infused with sedatives and analgesics throughout the study, which probably contributed to the low CMRO 2 . In contrast, the hyperthermia observed in patients would be expected to increase CMRO 2 . 28 Patients were hypocapnic compared with controls; this reduces CBF in meningitis patients and volunteers but affects CMRO 2 in neither patients nor volunteers. 10 We studied sedated and mechanically ventilated patients early during pneumococcal meningitis. The major pathophysiologic events of bacterial meningitis, intrathecal inflammation and blood-brain barrier dysfunction, occur irrespective of bacterial cause. 29 Accordingly, the findings can probably be generalized also to patients with meningitis caused by other bacteria than pneumococci. However, extrapolation of the results to less severely affected patients or to the late phase of meningitis may not be justified. 1 The clinical implications of this study are that the cerebrovascular effect of norepinephrine in meningitis patients is mediated solely through its influence on MAP. Thus, increasing MAP by norepinephrine infusion will increase CBF because of impaired autoregulation, and not because of an increase in cerebral metabolism. Secondly, the reduction in a-vDO 2 during propofol infusion suggests that cerebral metabolic coupling is impaired during the early phase of meningitis; thus, global CBF decreases relatively less than oxidative metabolism during propofol sedation.
